Cell & gene therapy

Disease Area Cancer

05/30/2023 | Neil Ward | 4 min read

What do advances in sequencing technology mean for research in cancer genomics?

Research Field Cell & gene therapy

02/21/2023 | Angus Stewart | 6 min read

Can digital tools help cell and gene therapy evolve?

Research Field Cell & gene therapy

02/14/2023 | Eric Rhodes | 4 min read

Why 2023 is the year that antibody manufacturers should embrace CRISPR gene editing.

Research Field Cell & gene therapy

09/30/2022 | Michael R. Volkert | 5 min read

A gene therapy targeting a gene that regulates antioxidant action may effectively treat retinal degeneration

Research Field Cell & gene therapy

09/07/2022 | Geoffrey Potjewyd | 5 min read

Many drugs are applied to the eye, yet we have little to no quantitative data on ocular drug metabolism – until now…

Research Field Cell & gene therapy

08/24/2022 | Hamid Khoja | 4 min read

In regenerative medicines and therapeutics, fibroblasts can offer significant advantages over stem cells, says Hamid Khoja

Disease Area Cell & gene therapy

09/14/2021 | Stephanie Vine

Can genomic medicine usher in a new era of curative treatments for neurological diseases? Experts from Sangamo give their views

Disease Area Cancer

07/12/2021 | Sponsored by 10x Genomics

Unravel the complexity of cancer biology and reveal insights to advance human health

Research Field Cancer

12/24/2020 | James Strachan

Cell and gene therapies are now considered mainstream therapeutic modalities – with revolutionary potential. But that hasn’t always been the case…

Research Field Pain & critical care

07/23/2019

Sitting Down With… Mike Clayman, CEO of Flexion Therapeutics, Inc., Burlington, Massachusetts, USA.